ArticleInternational journal of genomics2026
Aflatoxin B1 Impairs TACE Efficacy Through Downregulated Carbonic Anhydrase 2: A Bioinformatics Analysis.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aflatoxin B1 Impairs TACE Efficacy Through Downregulated Carbonic Anhydrase 2: A Bioinformatics Analysis.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, and transcatheter arterial chemoembolization (TACE) remains the core locoregional therapeutic modality for patients with intermediate to advanced disease. However, a considerable proportion of patients exhibit nonresponse to this treatment, which highlights an urgent need to identify reliable predictive biomarkers and elucidate the underlying mechanisms. Environmental carcinogens such as aflatoxin B1 (AFB1) are closely associated with the initiation and progression of liver cancer, yet their impact on the therapeutic efficacy of TACE has not been systematically elucidated. In this study, we integrated transcriptomic profiling, single-cell RNA sequencing (scRNA-seq), immune infiltration analysis, and molecular docking techniques to investigate the molecular mechanisms underlying AFB1-associated TACE nonresponse in HCC. We performed differential expression analysis using public cohorts to screen for genes associated with TACE response status (278 differentially expressed genes [DEGs] identified in the GSE104580 dataset) and tumorigenesis and progression (1365 DEGs identified in the TCGA-LIHC database), as well as AFB1 exposure. Intersection analysis with the predicted targets of AFB1 was subsequently conducted to identify key regulatory molecules. Functional enrichment analysis was applied to clarify the potential biological pathways involved in TACE nonresponse, and molecular docking was used to evaluate the binding potential between AFB1 and the core target. Our findings revealed that carbonic anhydrase 2 (CA2) could bind stably to AFB1 (Vina score = -7.8 kcal/mol) and possessed diagnostic potential for distinguishing tumor samples from normal ones (AUC = 0.819). Meanwhile, CA2 was identified as the core molecule linking AFB1 exposure to TACE nonresponse, with its expression consistently downregulated in HCC tumor tissues, TACE nonresponders (log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.